A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir®

Abstract

Patient: Male, 59Final Diagnosis: Chromophobe renal cell carcinoma, stage IVSymptoms: Discomfort in the right hypochondriumMedication: Oncolytic virus RigvirClinical Procedure: Nephro-adrenalectomySpecialty: OncologyObjective:Unusual or unexpected effect of treatmentBackground:Renal cell carcinoma is the most commonly diagnosed primary malignant tumor of the kidney in adults, and includes the variant of chromophobe renal cell carcinoma. Despite new targeted therapies that improve progression-free survival (PFS) and overall survival (OS) for early-stage renal cell carcinoma, the 5-year survival for patients with stage IV renal cell carcinoma remains below 10%, and the 50% OS is less than one year. Metastatic renal cell carcinoma can be resistant to cytotoxic chemotherapy. This report is of a case of stage IV chromophobe renal cell carcinoma that responded well to treatment with the oncolytic ECHO-7 virus, Rigvir®.Case Report:In December 2015, a 59-year-old man presented with a right-sided chromophobe renal cell carcinoma stage IV (pT1N0M1) with adrenal gland metastasis. He underwent right nephro-adrenalectomy followed by treatments with Rigvir® (≥106 TCID50/ml) by intramuscular (i.m.) injection on three consecutive days. Treatment with Rigvir® continued once per week for three months, and from March 2016, once per month, with continued treatment until computed tomography (CT) scans confirmed that the tumor metastases had stabilized.Conclusions:This case report has demonstrated that the oncolytic ECHO-7 virus, Rigvir® should be evaluated further as a potential treatment for advanced renal carcinoma.

Sarcomatoid Chromophobe Renal Cell Carcinoma: A Case Report and Review of the Literature

“…Chemotherapy regimen and targeted therapies showed little activity in SRCC [16]. Renal cell cancer has previously been reported to show sensitivity to immunotherapy, indicating the possible advantage of immunomodulating therapies over standard treatment [17]. Prospective trials assessing new drugs, including immune checkpoint inhibitors, are currently ongoing study on improved SRCC survival [16].…”

“…Renal cell cancer has previously been reported to show sensitivity to immunotherapy, indicating the possible advantage of immunomodulating therapies over standard treatment [17].…”

The Clinical Advances of Oncolytic Viruses in Cancer Immunotherapy

“…The follow-up CT imaging for more than one year, showed no disease progression, cancer metastasis, or lymph node involvement. Despite the estimated OS for patients with RCC stage 4, which equals less than 26 months, the patient survived over 33.7 months (remaining alive at the time of the report) and he never received any medical treatment except Rigvir [100].…”

Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives

“…Another research showed similar results in evaluating the effect of Rigivir on small cell lung cancer and histiocytic sarcoma [ 199 ]. In 2015, Zaurbek et al [ 200 ] described a clinical case of advanced renal cell cancer that responded well to Rigvir treatment: tumor metastases are stabilized three months after the treatment. These promising results have reinforced the opinion that Rigvir could significantly prolong survival in patients without serious side effects and it could be recommended in long-term treatment.…”